The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiopharma Cred. Regulatory News (BPCR)

Share Price Information for Biopharma Cred. (BPCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.84
Bid: 0.84
Ask: 0.852
Change: 0.00 (0.00%)
Spread: 0.012 (1.429%)
Open: 0.84
High: 0.00
Low: 0.00
Prev. Close: 0.84
BPCR Live PriceLast checked at -
BioPharma Credit is an Investment Trust

To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

14 Mar 2018 17:15

RNS Number : 7584H
BioPharma Credit PLC
14 March 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

BioPharma Credit PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Phemus Corporation

City and country of registered office (if applicable)

Boston, Massachusetts USA

4. Full name of shareholder(s) (if different from 3.)v

Name

N/A

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

20 February 2018

 

6. Date on which issuer notified (DD/MM/YYYY):

12 March 2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Less than 3%

N/A

Less than 3%

Less than 3%

Position of previous notification (if

applicable)

4.3%

-

4.3%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD USD0.01

GB00BDGKMY29

0

-

0%

-

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

0

0%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

Correction of a previous notification

     

 

Place of completion

Boston, Massachusetts USA

Date of completion

14 March 2018

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUSVNRWOAOAAR
Date   Source Headline
8th Feb 20247:00 amRNSDividend Declaration
7th Feb 20246:15 pmRNSTransaction in Own Shares
6th Feb 20246:15 pmRNSTransaction in Own Shares
6th Feb 20247:00 amRNSSTATEMENT RE COHERUS BIOSCIENCES, INC.
1st Feb 202410:39 amRNSTotal Voting Rights
31st Jan 20244:00 pmRNSNet Asset Value(s) and Monthly Factsheet
30th Jan 20246:15 pmRNSTransaction in Own Shares
29th Jan 20246:15 pmRNSTransaction in Own Shares
26th Jan 20246:15 pmRNSTransaction in Own Shares
25th Jan 20246:15 pmRNSTransaction in Own Shares
24th Jan 20246:15 pmRNSTransaction in Own Shares
23rd Jan 20246:15 pmRNSTransaction in Own Shares
22nd Jan 20246:15 pmRNSTransaction in Own Shares
22nd Jan 202412:35 pmRNSDirector/PDMR Shareholding
19th Jan 20246:15 pmRNSTransaction in Own Shares
18th Jan 20246:15 pmRNSTransaction in Own Shares
17th Jan 20246:15 pmRNSTransaction in Own Shares
16th Jan 20246:15 pmRNSTransaction in Own Shares
15th Jan 20246:15 pmRNSTransaction in Own Shares
12th Jan 20246:15 pmRNSTransaction in Own Shares
11th Jan 20246:15 pmRNSTransaction in Own Shares
10th Jan 20246:15 pmRNSTransaction in Own Shares
10th Jan 202410:36 amRNSTransaction in Own Shares
8th Jan 20246:15 pmRNSTransaction in Own Shares
5th Jan 20246:15 pmRNSTransaction in Own Shares
3rd Jan 20246:15 pmRNSTransaction in Own Shares
2nd Jan 20246:15 pmRNSTransaction in Own Shares
2nd Jan 20247:00 amRNSUPDATE ON INVESTMENT
28th Dec 202311:04 amRNSResult of General Meeting
21st Dec 20234:00 pmRNSNet Asset Value(s) and Monthly Factsheet
11th Dec 202311:25 amRNSUPDATE ON INVESTMENT
7th Dec 20236:04 pmRNSPUBLICATION OF CIRCULAR AND NOTICE OF GM
1st Dec 20237:00 amRNSSTATEMENT RE IMMUNOGEN, INC.
29th Nov 20237:00 amRNSDIVIDEND DECLARATION
22nd Nov 20237:01 amRNSUPDATE ON INVESTMENT
22nd Nov 20237:00 amRNSNET ASSET VALUE(S)
2nd Nov 20237:00 amRNSUPDATE ON INVESTMENT
1st Nov 20237:00 amRNSUPDATE ON INVESTMENT
1st Nov 20237:00 amRNSTRIGGER OF A CONTINUATION RESOLUTION
31st Oct 20233:30 pmRNSDirector Declaration
24th Oct 20237:00 amRNSUPDATE ON INVESTMENT
20th Oct 20234:00 pmRNSNet Asset Value(s) and Monthly Factsheet
12th Oct 20237:00 amRNSUPDATE ON INVESTMENT
2nd Oct 20231:32 pmRNSDirector/PDMR Shareholding
27th Sep 20237:00 amRNSHalf-year Report
26th Sep 202311:20 amRNSUPDATE ON INVESTMENT
22nd Sep 20234:00 pmRNSNet Asset Value(s) and Monthly Factsheet
19th Sep 20237:00 amRNSUpdate on Investment
31st Aug 20237:00 amRNSNotice of Half Year Results
29th Aug 202311:25 amRNSUpdate on Investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.